BRPI0814267A2 - Cytotoxic agents comprising novel tomaicmycin derivatives and their therapeutic use. - Google Patents

Cytotoxic agents comprising novel tomaicmycin derivatives and their therapeutic use.

Info

Publication number
BRPI0814267A2
BRPI0814267A2 BRPI0814267A BRPI0814267A2 BR PI0814267 A2 BRPI0814267 A2 BR PI0814267A2 BR PI0814267 A BRPI0814267 A BR PI0814267A BR PI0814267 A2 BRPI0814267 A2 BR PI0814267A2
Authority
BR
Brazil
Prior art keywords
tomaicmycin
derivatives
novel
therapeutic use
cytotoxic agents
Prior art date
Application number
Other languages
Portuguese (pt)
Inventor
Hervé Bouchard
Ravi V J Chari
Alain Commerçon
Yonghong Deng
Laurence Gauzy
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39048765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814267(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0814267A2 publication Critical patent/BRPI0814267A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0814267 2007-07-19 2008-07-18 Cytotoxic agents comprising novel tomaicmycin derivatives and their therapeutic use. BRPI0814267A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290904.7A EP2019104B1 (en) 2007-07-19 2007-07-19 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
PCT/IB2008/002869 WO2009016516A2 (en) 2007-07-19 2008-07-18 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
BRPI0814267A2 true BRPI0814267A2 (en) 2015-03-31

Family

ID=39048765

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814267 BRPI0814267A2 (en) 2007-07-19 2008-07-18 Cytotoxic agents comprising novel tomaicmycin derivatives and their therapeutic use.

Country Status (40)

Country Link
US (1) US8404678B2 (en)
EP (2) EP2019104B1 (en)
JP (1) JP5551070B2 (en)
KR (1) KR101627871B1 (en)
CN (1) CN101784550B (en)
AR (1) AR067575A1 (en)
AT (1) ATE530553T1 (en)
AU (1) AU2008281439B2 (en)
BR (1) BRPI0814267A2 (en)
CA (1) CA2693551C (en)
CL (1) CL2008002139A1 (en)
CO (1) CO6290692A2 (en)
CR (1) CR11225A (en)
CY (2) CY1112278T1 (en)
DK (2) DK2019104T3 (en)
DO (1) DOP2010000014A (en)
EA (1) EA019938B1 (en)
EC (1) ECSP109875A (en)
ES (2) ES2435779T3 (en)
GT (1) GT201000008A (en)
HK (1) HK1144289A1 (en)
HR (1) HRP20120067T1 (en)
IL (1) IL203318A (en)
JO (1) JO2744B1 (en)
MA (1) MA31617B1 (en)
ME (1) ME00969B (en)
MY (1) MY151245A (en)
NI (1) NI201000005A (en)
NZ (1) NZ582679A (en)
PA (1) PA8790201A1 (en)
PE (2) PE20090889A1 (en)
PL (2) PL2019104T3 (en)
PT (2) PT2019104E (en)
RS (1) RS52245B (en)
SI (2) SI2019104T1 (en)
TN (1) TN2010000002A1 (en)
TW (1) TWI500618B (en)
UA (1) UA98153C2 (en)
WO (1) WO2009016516A2 (en)
ZA (1) ZA201000389B (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662096A1 (en) 2005-08-24 2013-11-13 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
DE102008056086A1 (en) * 2008-11-06 2010-05-12 Gp Solar Gmbh An additive for alkaline etching solutions, in particular for texture etching solutions and process for its preparation
RU2683325C2 (en) * 2009-02-05 2019-03-28 Иммьюноджен, Инк. New benzodiazepine derivatives
AU2015224492B2 (en) * 2009-02-05 2017-04-20 Immunogen, Inc. Novel benzodiazepine derivatives
MX349210B (en) 2009-06-03 2017-07-18 Immunogen Inc Conjugation methods.
FR2947269B1 (en) 2009-06-29 2013-01-18 Sanofi Aventis NEW ANTICANCER COMPOUNDS
FR2949469A1 (en) * 2009-08-25 2011-03-04 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ES2497566T3 (en) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
MA34277B1 (en) * 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
KR101687054B1 (en) 2010-04-15 2016-12-15 메디뮨 리미티드 Pyrrolobenzodiazepines used to treat proliferative diseases
EA024118B1 (en) 2010-04-15 2016-08-31 Сиэтл Дженетикс, Инк. Targeted pyrrolobenzodiazepine conjugates
BR112012032248A2 (en) 2010-06-23 2016-09-13 Metabolex Inc 5-ethyl-2- {4 - [- 4- (-4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine compositions
FR2963007B1 (en) * 2010-07-26 2013-04-05 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CN107335061B (en) 2011-02-15 2021-09-07 伊缪诺金公司 Cytotoxic benzodiazepine derivatives
MX339927B (en) 2011-03-29 2016-06-16 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process.
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
CN103987718A (en) 2011-09-20 2014-08-13 斯皮罗根有限公司 Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
CN103987384A (en) 2011-10-14 2014-08-13 西雅图基因公司 Pyrrolobenzodiazepines and targeted conjugates
CN110183470A (en) 2011-10-14 2019-08-30 麦迪穆有限责任公司 Pyrrolobenzodiazepines are tall and erect
MX341523B (en) 2011-10-14 2016-08-24 Medimmune Ltd Pyrrolobenzodiazepines.
ES2660233T3 (en) 2011-10-14 2018-03-21 Seattle Genetics, Inc. Pyrrolobenzodiazepines and directed conjugates
SG10201604747WA (en) * 2011-12-13 2016-08-30 Immunogen Inc Use of n-hydroxysuccinimide to improve conjugate stability
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
KR20150006000A (en) 2012-05-01 2015-01-15 제넨테크, 인크. Anti-pmel17 antibodies and immunoconjugates
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
SG11201500093TA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd79b antibodies
PE20150615A1 (en) 2012-07-09 2015-05-28 Genentech Inc IMMUNOCONJUGATES INCLUDING AN ANTI-CD22 ANTIBODY LINKED TO A PYRROLOBENZODIAZEPINE
RU2015106673A (en) 2012-08-02 2016-09-20 Дженентек, Инк. ANTIBODIES TO TYPE B ENDOTHELIN RECEPTOR (ETBR) AND IMMUNOCONJUGATES
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
WO2014055877A1 (en) * 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
PL2906298T3 (en) 2012-10-12 2019-04-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
PL2906251T3 (en) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP6367204B2 (en) 2012-10-12 2018-08-01 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
TR201815418T4 (en) 2012-10-12 2018-11-21 Adc Therapeutics Sa Pyrrolobenzodiazepine -anti-psma antibody conjugates.
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN104837502B (en) 2012-10-12 2018-08-10 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
PL3470086T3 (en) 2012-10-12 2021-05-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6133431B2 (en) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Use of hydrophilic conjugates and conjugation reactions between drug molecules and cell binding molecules
CA2901941C (en) * 2013-03-13 2020-04-07 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP2968494B1 (en) 2013-03-13 2018-11-14 Seattle Genetics, Inc. Activated carbon filtration for purification of benzodiazepine adcs
BR112015021965B1 (en) * 2013-03-13 2022-05-03 Medimmune Limited Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition, use thereof for the treatment of a proliferative disease and method of synthesis of said compounds
JP6436965B2 (en) 2013-03-14 2018-12-12 ジェネンテック， インコーポレイテッド Anti-B7-H4 antibody and immunoconjugate
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN105518027A (en) 2013-09-17 2016-04-20 豪夫迈·罗氏有限公司 Methods of using anti-LGR5 antibodies
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
TW201533060A (en) 2013-12-13 2015-09-01 Genentech Inc Anti-CD33 antibodies and immunoconjugates
KR20160092024A (en) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
RU2016150370A (en) 2014-05-22 2018-06-26 Дженентек, Инк. Antibodies and immunoconjugates against GPC3
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
KR102632830B1 (en) 2014-09-03 2024-02-02 이뮤노젠 아이엔씨 Cytotoxic benzodiazepine derivatives
SI3191135T1 (en) 2014-09-12 2021-01-29 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (en) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 Cysteine engineered antibody and conjugate
AR101846A1 (en) 2014-09-12 2017-01-18 Genentech Inc ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS
TW201625689A (en) 2014-09-12 2016-07-16 建南德克公司 Anti-B7-H4 antibodies and immunoconjugates
MX2017003472A (en) * 2014-09-17 2017-10-31 Genentech Inc Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines.
WO2016083468A1 (en) * 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN107428780B (en) 2015-01-14 2020-09-04 百时美施贵宝公司 Benzodiazepine dimers, conjugates thereof, and methods of making and using
WO2016115201A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA2990030A1 (en) 2015-06-23 2016-12-29 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017015495A1 (en) 2015-07-21 2017-01-26 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
CN107405408B (en) * 2015-12-21 2021-07-02 江苏恒瑞医药股份有限公司 Preparation method of antibody drug conjugate
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017180842A1 (en) 2016-04-15 2017-10-19 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
HRP20221298T1 (en) 2016-05-13 2022-12-23 Bioatla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN107469089B (en) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 PEG connector and aglucon drug conjugate
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
AU2017305170A1 (en) 2016-08-02 2019-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11697680B2 (en) 2016-11-21 2023-07-11 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
JP7203729B2 (en) 2016-11-23 2023-01-13 イミュノジェン・インコーポレーテッド Selective sulfonation of benzodiazepine derivatives
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
WO2018119196A1 (en) 2016-12-23 2018-06-28 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
SI3544636T1 (en) 2017-02-08 2021-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2926144T3 (en) 2017-04-18 2022-10-24 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201839001A (en) 2017-04-20 2018-11-01 美商伊繆諾金公司 Cytotoxic benzodiazepine derivatives and conjugates thereof
JP7408396B2 (en) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム combination therapy
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
JP7220203B2 (en) 2017-08-18 2023-02-09 メドイミューン・リミテッド pyrrolobenzodiazepine complex
IL301638B1 (en) 2017-09-29 2024-05-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
JP2021508714A (en) 2017-12-28 2021-03-11 イミュノジェン・インコーポレーテッド Benzodiazepine derivative
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020014482A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
AU2019317565A1 (en) 2018-08-08 2021-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
TW202029980A (en) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof
CN113508136A (en) 2018-12-21 2021-10-15 艾维迪提生物科学公司 Anti-transferrin receptor antibodies and uses thereof
US20220064324A1 (en) 2019-01-08 2022-03-03 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2022523333A (en) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド Anti-GAL3 antibody and its use
JP2022529583A (en) 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド Its complex with cytotoxic bis-benzodiazepine derivatives and cell binding agents for inhibiting aberrant cell proliferation or treating proliferative disorders
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
CA3161573A1 (en) 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
JP2023527638A (en) 2020-03-27 2023-06-30 アビディティー バイオサイエンシーズ，インク． Compositions and methods for treating facioscapulohumeral muscular dystrophy
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
JP2024526764A (en) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド How to Prevent Protein Aggregation
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (en) 1966-04-01 1968-02-05 Rhone Poulenc Sa New antibiotic and its method of preparation by culture of streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (en) 1992-03-25 2000-11-16 Immunogen Inc CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065.
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US7049311B1 (en) 1998-08-27 2006-05-23 Spirogen Limited Pyrrolbenzodiazepines
ES2276708T3 (en) 1999-11-24 2007-07-01 Immunogen, Inc. CYTOTOXIC AGENTS UNDERSTANDING TAXANS AND THERAPEUTIC USE.
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
PT1578446E (en) 2002-11-07 2015-07-22 Immunogen Inc Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
WO2004087716A1 (en) * 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Pyrrolo[(2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
WO2004091542A2 (en) 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
AU2004258955C1 (en) 2003-07-21 2012-07-26 Immunogen, Inc. A CA6 antigen-specific cytotoxic conjugate and methods of using the same
GB0321295D0 (en) * 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
US7511032B2 (en) * 2003-10-22 2009-03-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
JP5166861B2 (en) 2004-03-09 2013-03-21 スピロゲン リミティッド Pyrrolobenzodiazepine
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
EP1813614B1 (en) * 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
CA2658276A1 (en) * 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
PL2019104T3 (en) 2014-03-31
SI2019104T1 (en) 2013-12-31
EP2019104B1 (en) 2013-09-04
AU2008281439A1 (en) 2009-02-05
ATE530553T1 (en) 2011-11-15
CN101784550A (en) 2010-07-21
JP2010533703A (en) 2010-10-28
PT2019104E (en) 2013-12-03
UA98153C2 (en) 2012-04-25
WO2009016516A8 (en) 2009-04-16
EP2170890A2 (en) 2010-04-07
ES2435779T3 (en) 2013-12-23
US20100316656A1 (en) 2010-12-16
PA8790201A1 (en) 2009-02-09
CY1114922T1 (en) 2016-12-14
EP2019104A1 (en) 2009-01-28
KR101627871B1 (en) 2016-06-07
CY1112278T1 (en) 2015-12-09
TWI500618B (en) 2015-09-21
CR11225A (en) 2010-06-23
DK2170890T3 (en) 2012-02-27
HK1144289A1 (en) 2011-02-11
IL203318A (en) 2016-08-31
CL2008002139A1 (en) 2009-10-23
KR20100063021A (en) 2010-06-10
ME00969B (en) 2012-06-20
EA019938B1 (en) 2014-07-30
MA31617B1 (en) 2010-08-02
PT2170890E (en) 2012-02-03
WO2009016516A3 (en) 2009-06-11
AR067575A1 (en) 2009-10-14
WO2009016516A2 (en) 2009-02-05
SI2170890T1 (en) 2012-02-29
CA2693551C (en) 2016-09-20
JP5551070B2 (en) 2014-07-16
JO2744B1 (en) 2014-03-15
TW200922598A (en) 2009-06-01
NI201000005A (en) 2010-03-09
RS52245B (en) 2012-10-31
US8404678B2 (en) 2013-03-26
CN101784550B (en) 2014-06-11
CA2693551A1 (en) 2009-02-05
DK2019104T3 (en) 2013-12-16
HRP20120067T1 (en) 2012-02-29
TN2010000002A1 (en) 2011-09-26
EA201070163A1 (en) 2010-08-30
NZ582679A (en) 2012-04-27
GT201000008A (en) 2012-03-26
DOP2010000014A (en) 2010-02-15
PE20130590A1 (en) 2013-05-22
EP2170890B1 (en) 2011-10-26
ECSP109875A (en) 2010-02-26
AU2008281439B2 (en) 2013-02-07
ZA201000389B (en) 2011-04-28
PL2170890T3 (en) 2012-04-30
CO6290692A2 (en) 2011-06-20
PE20090889A1 (en) 2009-08-06
ES2376026T3 (en) 2012-03-08
MY151245A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
BRPI0814267A2 (en) Cytotoxic agents comprising novel tomaicmycin derivatives and their therapeutic use.
BRPI0810523A2 (en) 5-member heterocyclic derivative and use thereof for medical purposes.
DK1981889T3 (en) CYTOTOXIC AGENTS INCLUDING NEW TOMAYMYCIN DERIVATIVES AND THERAPEUTIC APPLICATION THEREOF
BRPI0813455A2 (en) 17BETA-CYAN-18A-HOMO-19-NOR-ANDROST-4-ENO DERIVATIVE, ITS USE AND MEDICINAL PRODUCTS CONTAINING THIS DERIVATIVE.
BRPI0720124A2 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
BRPI0920448A2 (en) spiro-oxindole compounds and their use as therapeutic agents
BRPI0718182A2 (en) OLIGORRIBONUCLEOTIDS AND THEIR USES.
BRPI1008045A2 (en) aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
BRPI0814963A2 (en) DIPEPTIDE PRODUCTS AND THEIR USE
BRPI0719345A2 (en) REPLACED DI-HYDROIMIDAZOLS AND ITS USE IN TREATMENT TREATMENT.
BRPI0821115A2 (en) Aminotriazole-derived compound, drug, pharmaceutical composition and use of compound
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
BRPI1010621A2 (en) imidazoquinolinones derivative, their pharmaceutical composition and their use
BRPI0908225A2 (en) pyridazine derivatives and their use as therapeutic agents
BRPI0813263A2 (en) REPLACED OXAZOLIDINONES AND THEIR USE
BRPI0813955A2 (en) therapeutic compositions and their use
BRPI0719166A2 (en) TRICYCLIC SPIRO-OXINDOL DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS
BRPI0816372A2 (en) REPLACED 6-PHENYLNICOTINIC ACIDS AND THEIR USE
BRPI0808798A2 (en) 3,5-DISSUBSTITUTED PHENOXYPHENYLAMIDINS AND THEIR USE AS FUNGICIDES
BRPI0810654A2 (en) Thiadiazolyloxyphenylamidines and their use as fungicides.
CR10725A (en) PIRAZOLINE COMPOUNDS AND THEIR USE AND PHARMACEUTICAL COMPOSIONS
BRPI0915552A2 (en) cyclosporine derivatives, their use and pharmaceutical composition
BRPI0818690A2 (en) Quinazolinedione derivatives, their preparation and their therapeutic uses.
BRPI0817542A2 (en) New sEH inhibitors and their use
ATE420081T1 (en) TRIFLUORMETHYLBENZAMIDE DERIVATIVES AND THERAPEUTIC USES THEREOF

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL